Journals / Journal of the Turkish Chemical Society Section A: Chemistry / 2020 / Cilt: 7 - Sayı: 3

Stability Indicating Liquid Chromatographic Method for the Simultaneous Determination of Rosuvastatin and Ezetimibe from Pharmaceuticals and Biological Samples

Pages
865–874
Publication Date
2020-10-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Moreover, we further used the established method for to the analysis of ezetimibe and rosuvastatin from real spiked samples of rabbit serum.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fixed dose combinations of ezetimibe and rosuvastatin are well known to provide significantly superior efficacy to rosuvastatin alone in lowering total cholesterol, and triglyceride levels.
📊
Key Findings & Data:Therefore, in this recent work, we prepared fixed dose (10mg/10mg) ezetimibe and rosuvastatin tablet formulations, and a simple, selective and we established and validated rapid chromatographic method for the sensitive and simultaneous determination of rosuvastatin and ezetimibe.
💡
Conclusion & Impact:Moreover, we further used the established method for to the analysis of ezetimibe and rosuvastatin from real spiked samples of rabbit serum.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Rosuvastatin · Ezetimibe · Liquid Chromatography

Abstract

Fixed dose combinations of ezetimibe and rosuvastatin are well known to provide significantly superior efficacy to rosuvastatin alone in lowering total cholesterol, and triglyceride levels. Therefore, in this recent work, we prepared fixed dose (10mg/10mg) ezetimibe and rosuvastatin tablet formulations, and a simple, selective and we established and validated rapid chromatographic method for the sensitive and simultaneous determination of rosuvastatin and ezetimibe. We performed the separation on Zorbax SB-C18 (100 mm x 4.6 mm, 3.5 µm particle size) column at 30 oC with a mobile phase that has a composition as water containing 0.1% H3PO4:methanol:acetonitrile (50:25:25 v/v/v) at 1.2 mL/min flow rate. We further performed validation studies according to ICH guidelines. Furthermore, we exposed rosuvastatin and ezetimibe to degradation conditions. We plotted peak area vs. concentration graphs for rosuvastatin and ezetimibe and used for defining the linearity of the detector response. In this suggested method, we observed linear relationships varying from 0.05 to 50 µg/mL for ezetimibe concentrations and from 0.05 to 25 µg/mL for rosuvastatin concentrations. We found the limit of detection values for rosuvastatin and ezetimibe as 0.006 and 0.008 µg/mL, respectively. Moreover, we further used the established method for to the analysis of ezetimibe and rosuvastatin from real spiked samples of rabbit serum.

🔖

Cite This Article

KURBANOĞLU, S., ESİM, O., KOSE, C., SAVAŞER, A., OZKAN, Y., USLU, B., ÖZKAN, S. (2020). Stability Indicating Liquid Chromatographic Method for the Simultaneous Determination of Rosuvastatin and Ezetimibe from Pharmaceuticals and Biological Samples. Journal of the Turkish Chemical Society Section A: Chemistry, Cilt: 7 - Sayı: 3, 865–874. https://ajindex.com/articles/781198

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Schultheis A. Hypercholesterolemia: prevention, detection and management. Nurse Pract. 1990;15:40–6
  2. Ross R. The Pathogenesis of Atherosclerosis — An Update. Vol. 314, New England Journal of Medicine. 1986. p. 488–500
  3. Ornish D, Brown SE, Billings JH, Scherwitz LW, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease?. The Lifestyle Heart Trial. Lancet. 1990 Jul 21;336(8708):129–33
  4. Ulbricht TLV, Southgate DAT. Coronary heart disease: seven dietary factors. Lancet. 1991 Oct 19;338(8773):985–92
  5. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: Characteristics of rosuvastatin. In: Atherosclerosis Supplements. 2002. p. 33–7
  6. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20(8):1185–95
  7. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084–91
  8. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23(8):1209–30
  9. Nutescu EA, Shapiro NL. Ezetimibe: A Selective Cholesterol Absorption Inhibitor. Pharmacotherapy. 2003;23(11):1463–74
  10. McTaggart F. Comparative pharmacology of rosuvastatin. In: Atherosclerosis Supplements. Elsevier Ireland Ltd; 2003. p. 9–14
  11. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. In: American Journal of Cardiology. Elsevier Inc.; 2001. p. 28–32
  12. Stein EA. Management of hypercholesterolemia. Approach to diet and drug therapy. Am J Med. 1989;87(SUPPL. 4)
  13. Davidson MH. Rosuvastatin: A highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002;11(1):125–32
  14. Shah Y, Iqbal Z, Ahmad L, Khan A, Khan MI, Nazir S, et al. Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: Method development, validation and optimization of various experimental parameters. J Chromatogr B Anal Technol Biomed Life Sci. 2011 Mar 15;879(9–10):557–63
  15. Nasir F, Iqbal Z, Khan A, Ahmad L, Shah Y, Khan AZ, et al. Si